|
If
you are currently taking Bextra check with your doctor.
Withdrawal
On
April 7, 2005 the FDA announced that it has asked Pfizer, Inc.
to withdraw Bextra from the
market "because the overall risk versus benefit profile for
the drug is unfavorable."
bextra®
is a non-steroidal anti-inflammatory drug
(NSAIDs), known as a COX-2 selective agent. It is
prescribed for inflammation and pain from arthritis and menstrual
cramping. Other drugs in this class include Celebrex® and
Vioxx®. Bextra® and Celebrex® are both manufactured by Pfizer
and Vioxx® is manufactured by Merck.
Some doctors switched patients
from Vioxx® to Bextra® when Merck voluntarily removed it from the
market due studies showing an increased risk for heart attack
and stroke.
Bextra® added warnings
to it's box strengthening previous warnings about the risk of life-threatening
skin reactions and a new bolded warning contraindicating
it's use for patients undergoing coronary artery bypass surgery.
February 16 - 18, 2005 there were
Joint Meetings of the Arthritis Advisory Committee and
the Drug Safety and Risk Management Advisory Committee to
discuss the COX-2 selective non-steroidal anti-inflammatory drugs
and related agents in Washington DC.
bextra
site map
Click
here to read the FDA questions and answers about strengthened warnings on Bextra®
boxes
http://www.fda.gov/cder/drug/infopage/bextra/bextraQA.htm
To report any unexpected
adverse or serious events associated with the use of Bextra®
contact the FDA MedWatch program at: 1-800-FDA-1088 or on the
Internet at http://www.fda.gov/medwatch/index.html
Scroll
to the bottom of this page to find a lawyer in your state:
http://www.defectivedrugsfyi.com/bextra.html
Autism
Education Materials!
|
